Jaguar Health subsidiary Napo enters new 3-year manufacturing agreement with Alivus for crofelemer supply

Jaguar Health, Inc.

New agreement with Alivus Life Sciences for manufacture of crofelemer for Mytesi and other products.
Term from July 9, 2026 to March 31, 2029; replaces prior agreement that expired March 31, 2026.
Includes minimum purchase quantities; shortfall payment obligation if not met.
May be terminated for any reason with 12 months' notice, or for material breach with 90-day cure.
In insolvency, rights assigned to Woodward Specialty LLC (affiliate of Future Pak).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.